Clinical development of oncolytic viruses in China
Related Experiment Video
Updated: May 31, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
1TOT Shanghai R&D Center, China. liangmin@hotmail.com
Abstract:
The oncolytic virus, being a promising new therapeutic strategy for cancer, has inspired a wave of recent clinical research and development in China. The first commercialized oncolytic virus, Oncorine, was approved by Chinese SFDA in November 2005 for nasopharyngeal carcinoma combined with chemotherapy. Since then, a number of oncolytic viruses have been moved into clinical trials. Among these are the armed oncolytic adenoviruses such as H103 (expressing the heat shock protein) currently has finished phase I trial, and KH901 (expressing GM-CSF) now launched in phase II trial In this review, we will discuss the current status of ongoing oncolytic virus projects being conducted at various clinical stages in China, including the preliminary market response for Oncorine after it was launched into the Chinese market in 2006.
Insights
China is advancing oncolytic virus therapy for cancer. Research includes Oncorine, the first approved virus, and novel adenoviruses in clinical trials, showing significant progress in cancer treatment development.
Area of Science:
- Oncolytic virotherapy
- Cancer therapeutics
- Chinese pharmaceutical development
Background:
- Oncolytic viruses represent a promising cancer treatment strategy.
- China has seen significant clinical research and development in this field.
- The first commercialized oncolytic virus, Oncorine, was approved in China in 2005.
Purpose of the Study:
- To review the current status of oncolytic virus projects in China.
- To discuss ongoing clinical trials and development stages.
- To assess the market response of Oncorine.
Main Methods:
- Review of clinical research and development in China.
- Analysis of approved and investigational oncolytic viruses.
- Examination of clinical trial progress (Phase I, Phase II).
- Assessment of market data for Oncorine.
Main Results:
- Oncorine, approved in 2005, was launched in the Chinese market in 2006.
- Several oncolytic viruses, including armed adenoviruses, are in clinical trials.
- H103 (heat shock protein) completed Phase I; KH901 (GM-CSF) is in Phase II.
Conclusions:
- China is actively progressing with oncolytic virus therapies.
- Ongoing clinical trials indicate a robust pipeline for novel cancer treatments.
- The development and market introduction of Oncorine highlight China's role in advancing virotherapy.
Related Concept Videos
01:28Preclinical Development: Overview
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...